Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus vaginal suppository for endometrial dysbiosis and chronic endometritis in recurrent implantation failure
jRCTs031220184Suspended
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Randomised, single-blind trial in endometritis, Endometrial dysbiosis and Recurrent Implantation Failure (RIF) comparing Lactobacillus vaginal suppository with Placebo / then Lactobacillus open-label (2 arms). Primary endpoint: Change in endometrial Lactobacillus occupancy. Started Nov 2022; status: suspended.
02
Drugs
lactobacillus-containing vaginal suppository
03
Conditions
endometritisEndometrial dysbiosisRecurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on jRCTs031220184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220184.